Prognostic Role of RNA Expression Molecular Biomarkers in Prostate and Bladder Cancers.

Ahmed, Mohamed E; Todenhöfer, Tilman; Karnes, R Jeffrey; Seiler, Roland (2022). Prognostic Role of RNA Expression Molecular Biomarkers in Prostate and Bladder Cancers. European urology focus, 8(3), pp. 663-666. Elsevier 10.1016/j.euf.2022.06.009

Text 1-s2.0-S2405456922001389-main.pdf - Published Version Restricted to registered users only Available under License Publisher holds Copyright. Download (195kB) | Request a copy

Prostate cancer and bladder cancer are two of the most common urologic cancers. Cancer risk stratification and prediction of prognosis have always been challenging. Following recent advances in genomic and proteomic technologies, several genomic biomarkers have been developed and proposed as a noninvasive and nonexpansive approach that can supplement our current data to improve prediction and accuracy. Several biomarkers have shown efficacy in patient risk stratification and in predicting prognosis. Here we provide a mini-review of current RNA biomarkers approved by the US Food and Drug Administration, including the Decipher, Oncotype DX Prostate, and Prolaris tests. We also provide a summary of their approved clinical utility in prostate cancer and bladder cancer management. PATIENT SUMMARY: A number of tests are available for measuring expression levels of genes related to prostate or bladder cancer. We review the usefulness of these tests in stratifying risk for patients and predicting their prognosis.

Interest & Impact

Downloads

1 since deposited on 20 Jul 2022
1 in the past 12 months

Citations

5 Citations in Web of Science ®
6 Citations in Scopus

Search

in Google Scholar™

Services

Actions (login required)

Edit item

Actions (login required)

Edit item